The emergence of oral glucagon-like peptide-1 (GLP-1) receptor agonists marks a significant advancement in obesity pharmacotherapy, offering needle-free alternatives to injectable agents. In this context, a new population-adjusted indirect treatment comparison (ITC), to be presented at the Obesity Medicine Association (OMA) 2026 annual meeting, evaluated the relative efficacy and tolerability of oral semaglutide 25 mg (Wegovy® pill) versus orforglipron 36 mg.
The analysis leveraged data from key phase 3 clinical trials, including OASIS 4 (oral semaglutide) and ATTAIN-1 (orforglipron), applying established indirect comparison methodologies to account for cross-trial differences. Results demonstrated that oral semaglutide achieved significantly greater mean weight reduction compared with orforglipron. Quantitatively, the difference in weight loss was estimated at approximately 3 percentage points in favor of semaglutide, indicating a clinically meaningful advantage in efficacy.
In addition to superior weight loss outcomes, oral semaglutide showed a more favorable tolerability profile. The odds of treatment discontinuation due to gastrointestinal adverse events were markedly higher with orforglipron—approximately 14-fold greater compared with semaglutide. This suggests that tolerability may represent a key differentiator between the two oral agents, particularly in long-term weight management where adherence is critical. Patient-centered outcomes further reinforced these findings. In a separate preference study, a substantial majority (84%) of participants favored a treatment profile resembling oral semaglutide over one similar to orforglipron. These preferences likely reflect the combined impact of efficacy, tolerability, and overall treatment experience
These results are particularly timely given the recent regulatory approval of orforglipron, expanding the competitive landscape of oral anti-obesity therapies. While both agents represent important therapeutic advances, the indirect comparison suggests that oral semaglutide may offer advantages in both effectiveness and persistence on therapy. However, it is important to interpret these findings within the limitations of indirect comparisons, including potential residual confounding and differences in trial populations.
In conclusion, this analysis provides early comparative insights into two leading oral GLP-1 therapies, indicating that Wegovy® tablets may deliver superior weight loss and improved tolerability relative to orforglipron. These findings may help inform clinical decision-making as oral options for obesity management continue to evolve.
